Biomarker Tracking
131 biomarkers from Superpower and Function Health. Filter by blood draw date, export as JSON or CSV.
This is one person's data. Biomarker values fluctuate naturally between draws — a single value is not diagnostic. “Flagged” means outside optimal range, not necessarily a problem. Use this to inform conversations with your doctor, not to self-diagnose.
Blood draw:
131 markers
Overview (3)Heart & Vascular Health (28)Metabolic Health (13)Inflammation (12)Sex Hormones (15)Thyroid Health (7)Liver Health (9)Kidney Health (4)Nutrients (15)Energy (2)Immune System (13)DNA Health (3)Brain Health (1)Gut Health (5)Cardiovascular (1)
Health Score
Biological Age
Pace of Aging
| Marker | Value | Unit | Status | Change | Date |
|---|---|---|---|---|---|
| Health Score | 86 | points | OPTIMAL | +6% | Feb 9 |
| Biological Age | 39.7 | years | HIGH | +2% | Feb 9 |
| Pace of Aging | 104 | % | HIGH | +2% | Feb 9 |
Cholesterol, Total
LDL Cholesterol
HDL Cholesterol
Triglycerides
Apolipoprotein B
LDL/HDL Ratio
Non-HDL Cholesterol
Cholesterol/HDL Ratio
Neutrophil-to-HDL Cholesterol Ratio (NHR)
Atherogenic Coefficient
Atherogenic Index of Plasma
Castelli Risk Index I
LDL Cholesterol / Total Cholesterol (Mass Ratio)
LDL-C to Apolipoprotein B Ratio (LDL-C/ApoB)
NON-HDL Total Cholesterol Ratio
Non-HDL Cholesterol-to-Apolipoprotein B Ratio (Non-HDL-C/ApoB)
Triglyceride HDL Molar Ratio
Triglyceride-to-Apolipoprotein B Ratio (TG/ApoB)
Monocyte-to-HDL Ratio (MHR)
| Marker | Value | Unit | Status | Change | Date |
|---|---|---|---|---|---|
| Cholesterol, Total | 148 | mg/dL | OPTIMAL | -14% | Feb 9 |
| LDL Cholesterol | 85 | mg/dL | NORMAL | -9% | Feb 9 |
| HDL Cholesterol | 49 | mg/dL | NORMAL | -26% | Feb 9 |
| Triglycerides | 64 | mg/dL | OPTIMAL | +19% | Feb 9 |
| Apolipoprotein B | 99 | mg/dL | HIGH | +24% | Feb 9 |
| Lipoprotein (a) | 21 | nmol/L | OPTIMAL | -- | Nov 21 |
| HDL Size | 9.3 | nm | OPTIMAL | -- | Nov 21 |
| HDL-P (Total) | 39.4 | umol/L | OPTIMAL | -- | Nov 21 |
| LDL Size | 21.1 | nm | OPTIMAL | -- | Nov 21 |
| LDL-P | 1228 | nmol/L | NORMAL | -- | Nov 21 |
| LDL/HDL Ratio | 1.7 | OPTIMAL | +21% | Feb 9 | |
| Non-HDL Cholesterol | 99 | mg/dL | OPTIMAL | -7% | Feb 9 |
| Small LDL-P | 439 | nmol/L | OPTIMAL | -- | Nov 21 |
| VLDL Size | 48.6 | nm | NORMAL | -- | Nov 21 |
| Large VLDL-P | 1.5 | nmol/L | OPTIMAL | -- | Nov 21 |
| Large HDL-P | 8.7 | umol/L | OPTIMAL | -- | Nov 21 |
| Cholesterol/HDL Ratio | 3 | OPTIMAL | +15% | Feb 9 | |
| Neutrophil-to-HDL Cholesterol Ratio (NHR) | 70.79 | ratio | OPTIMAL | +17% | Feb 9 |
| Atherogenic Coefficient | 2.02 | ratio | OPTIMAL | +25% | Feb 9 |
| Atherogenic Index of Plasma | -0.25 | score | OPTIMAL | +44% | Feb 9 |
| Castelli Risk Index I | 3.02 | ratio | OPTIMAL | +15% | Feb 9 |
| LDL Cholesterol / Total Cholesterol (Mass Ratio) | 0.57 | ratio | OPTIMAL | +8% | Feb 9 |
| LDL-C to Apolipoprotein B Ratio (LDL-C/ApoB) | 0.85 | ratio | LOW | -27% | Feb 9 |
| NON-HDL Total Cholesterol Ratio | 0.66 | ratio | OPTIMAL | +8% | Feb 9 |
| Non-HDL Cholesterol-to-Apolipoprotein B Ratio (Non-HDL-C/ApoB) | 1 | ratio | LOW | -25% | Feb 9 |
| Triglyceride HDL Molar Ratio | 1.3 | ratio | NORMAL | +60% | Feb 9 |
| Triglyceride-to-Apolipoprotein B Ratio (TG/ApoB) | 0.64 | ratio | OPTIMAL | -4% | Feb 9 |
| Monocyte-to-HDL Ratio (MHR) | 9.91 | ratio | OPTIMAL | +24% | Feb 9 |
Glucose
Hemoglobin A1c
TyG Index
Uric Acid-to-HDL Cholesterol Ratio (UHR)
Sodium
Potassium
Chloride
Carbon Dioxide, Total
Uric Acid
Eag (mmol/l)
Estim. Avg Glu (eAG)
| Marker | Value | Unit | Status | Change | Date |
|---|---|---|---|---|---|
| Glucose | 83 | mg/dL | OPTIMAL | +1% | Feb 9 |
| Hemoglobin A1c | 5 | % | OPTIMAL | -6% | Feb 9 |
| Insulin | 5 | uIU/mL | OPTIMAL | -- | Nov 21 |
| TyG Index | 7.88 | index | OPTIMAL | +2% | Feb 9 |
| Uric Acid-to-HDL Cholesterol Ratio (UHR) | 0.12 | ratio | OPTIMAL | +100% | Feb 9 |
| Sodium | 138 | mmol/L | OPTIMAL | -- | Feb 9 |
| Potassium | 4.8 | mmol/L | NORMAL | +17% | Feb 9 |
| Chloride | 104 | mmol/L | OPTIMAL | +2% | Feb 9 |
| Carbon Dioxide, Total | 23 | mmol/L | NORMAL | -4% | Feb 9 |
| Uric Acid | 5.9 | mg/dL | NORMAL | +40% | Feb 9 |
| Eag (mmol/l) | 5.4 | mmol/L | OPTIMAL | -7% | Feb 9 |
| Estim. Avg Glu (eAG) | 97 | mg/dL | OPTIMAL | -8% | Feb 9 |
| Body Mass Index (BMI) | 26.22 | kg/m2 | NORMAL | -- | Dec 16 |
Ferritin-to-Albumin Ratio
Lymphocyte-to-Monocyte Ratio (LMR)
Monocyte-to-Lymphocyte Ratio (MLR)
Neutrophil-to-Lymphocyte Ratio (NLR)
Neutrophil-to-Lymphocyte-Platelet Ratio (NLPR)
Platelet-to-Lymphocyte Ratio (PLR)
Platelet-to-WBC Ratio (PWR)
Systemic Inflammation Response Index (SIRI)
High-sensitivity CRP
hsCRP-to-Albumin Ratio (CAR)
Systemic Immune-Inflammation Index
| Marker | Value | Unit | Status | Change | Date |
|---|---|---|---|---|---|
| Ferritin-to-Albumin Ratio | 35.74 | ratio | HIGH | +7% | Feb 9 |
| Lymphocyte-to-Monocyte Ratio (LMR) | 4.14 | ratio | OPTIMAL | -16% | Feb 9 |
| Monocyte-to-Lymphocyte Ratio (MLR) | 0.24 | ratio | OPTIMAL | +20% | Feb 9 |
| Neutrophil-to-Lymphocyte Ratio (NLR) | 1.72 | ratio | OPTIMAL | +11% | Feb 9 |
| Neutrophil-to-Lymphocyte-Platelet Ratio (NLPR) | 0.56 | ratio | OPTIMAL | -5% | Feb 9 |
| Platelet-to-Lymphocyte Ratio (PLR) | 0.14 | ratio | OPTIMAL | +40% | Feb 9 |
| Platelet-to-WBC Ratio (PWR) | 47.18 | ratio | OPTIMAL | +32% | Feb 9 |
| Systemic Inflammation Response Index (SIRI) | 836.27 | ratio | OPTIMAL | +3% | Feb 9 |
| Erythrocyte Sedimentation Rate | 2 | mm/h | OPTIMAL | -- | Nov 21 |
| High-sensitivity CRP | 1 | mg/L | OPTIMAL | -71% | Feb 9 |
| hsCRP-to-Albumin Ratio (CAR) | 0.21 | ratio | OPTIMAL | -71% | Feb 9 |
| Systemic Immune-Inflammation Index | 519.66 | index | NORMAL | +29% | Feb 9 |
Testosterone, Bioavailable
Testosterone, Total
Free Testosterone
Estradiol
Sex Hormone Binding Globulin (SHBG)
DHEA-Sulfate (DHEA-S)
Testosterone-to-Estradiol Ratio (T/E₂)
| Marker | Value | Unit | Status | Change | Date |
|---|---|---|---|---|---|
| Free Androgen Index | 66.79 | % | OPTIMAL | -- | Nov 21 |
| Testosterone, Bioavailable | 168.8 | ng/dL | NORMAL | -9% | Feb 9 |
| Testosterone, Total | 722 | ng/dL | OPTIMAL | +17% | Feb 9 |
| Free Testosterone | 80.4 | pg/mL | NORMAL | -9% | Feb 9 |
| Estradiol | 32 | pg/mL | NORMAL | -20% | Feb 9 |
| Sex Hormone Binding Globulin (SHBG) | 44 | nmol/L | NORMAL | +38% | Feb 9 |
| Progesterone | 0.5 | ng/mL | OPTIMAL | -- | Nov 21 |
| Prolactin | 5.2 | ng/mL | OPTIMAL | -- | Nov 21 |
| Follicle Stimulating Hormone (FSH) | 3.5 | mIU/mL | OPTIMAL | -- | Nov 21 |
| Luteinizing hormone (LH) | 4 | mIU/mL | OPTIMAL | -- | Nov 21 |
| DHEA-Sulfate (DHEA-S) | 330 | mcg/dL | NORMAL | +2% | Feb 9 |
| Prostate Specific Antigen (PSA) | 0.9 | ng/mL | OPTIMAL | -- | Nov 21 |
| PSA % Free | 44 | % | OPTIMAL | -- | Nov 21 |
| PSA Free | 0.4 | ng/mL | OPTIMAL | -- | Nov 21 |
| Testosterone-to-Estradiol Ratio (T/E₂) | 2.25 | ratio | OPTIMAL | +46% | Feb 9 |
Thyroid-Stimulating Hormone (TSH)
T3 Uptake
Free Thyroxine Index
T4 (thyroxine) Total
| Marker | Value | Unit | Status | Change | Date |
|---|---|---|---|---|---|
| Thyroid-Stimulating Hormone (TSH) | 1.08 | mIU/L | OPTIMAL | -27% | Feb 9 |
| T3 Uptake | 33 | % | OPTIMAL | -8% | Feb 9 |
| Triiodothyronine (T3) | 3.3 | pg/mL | OPTIMAL | -- | Nov 21 |
| Free Thyroxine Index | 2.6 | N/A | OPTIMAL | -13% | Feb 9 |
| T4 (thyroxine) Total | 7.9 | mcg/dL | OPTIMAL | -4% | Feb 9 |
| Thyroid Peroxidase (TPO) Ab | 1 | IU/mL | OPTIMAL | -- | Nov 21 |
| Thyroglobulin Antibodies | 1 | IU/mL | OPTIMAL | -- | Nov 21 |
Aspartate Aminotransferase (AST)
Alanine Aminotransferase (ALT)
Alkaline Phosphatase (ALP)
Bilirubin, Total
y-Glutamyl Transferase (GGT)
Bilirubin Direct
Bilirubin Indirect
GGT-to-HDL Cholesterol Ratio
Indirect-to-Direct Bilirubin Ratio
| Marker | Value | Unit | Status | Change | Date |
|---|---|---|---|---|---|
| Aspartate Aminotransferase (AST) | 19 | U/L | OPTIMAL | +6% | Feb 9 |
| Alanine Aminotransferase (ALT) | 27 | U/L | NORMAL | +23% | Feb 9 |
| Alkaline Phosphatase (ALP) | 72 | U/L | OPTIMAL | -18% | Feb 9 |
| Bilirubin, Total | 0.5 | mg/dL | OPTIMAL | -- | Feb 9 |
| y-Glutamyl Transferase (GGT) | 23 | U/L | OPTIMAL | -15% | Feb 9 |
| Bilirubin Direct | 0.1 | mg/dL | OPTIMAL | -- | Feb 9 |
| Bilirubin Indirect | 0.4 | mg/dL | OPTIMAL | -- | Feb 9 |
| GGT-to-HDL Cholesterol Ratio | 0.46 | ratio | HIGH | +15% | Feb 9 |
| Indirect-to-Direct Bilirubin Ratio | 4 | ratio | OPTIMAL | -- | Feb 9 |
Blood Urea Nitrogen (BUN)
Creatinine
Estimated Glomerular Filtration Rate (eGFR)
Urea-to-Creatinine Ratio
| Marker | Value | Unit | Status | Change | Date |
|---|---|---|---|---|---|
| Blood Urea Nitrogen (BUN) | 17 | mg/dL | NORMAL | -11% | Feb 9 |
| Creatinine | 1.22 | mg/dL | NORMAL | +1% | Feb 9 |
| Estimated Glomerular Filtration Rate (eGFR) | 78 | mL/min/1.73m2 | NORMAL | -1% | Feb 9 |
| Urea-to-Creatinine Ratio | 13.93 | ratio | OPTIMAL | -11% | Feb 9 |
Corrected Calcium (Albumin-adjusted)
Vitamin D
Red Blood Cells
Hemoglobin
Hematocrit
Mean Cell Volume (MCV)
RDW MCV Ratio
Mean Cell Hemoglobin (MCH)
Mean Corpuscular Hemoglobin Concentration (MCHC)
Red Cell Dist Width (RDW)
Iron
Iron Saturation
Total Iron Binding Capacity (TIBC)
Ferritin
Calcium
| Marker | Value | Unit | Status | Change | Date |
|---|---|---|---|---|---|
| Corrected Calcium (Albumin-adjusted) | 9.03 | mg/dL | OPTIMAL | +2% | Feb 9 |
| Vitamin D | 82 | ng/mL | NORMAL | +78% | Feb 9 |
| Red Blood Cells | 4.78 | x10E6/uL | OPTIMAL | -3% | Feb 9 |
| Hemoglobin | 14.8 | g/dL | OPTIMAL | -4% | Feb 9 |
| Hematocrit | 45.6 | % | OPTIMAL | +1% | Feb 9 |
| Mean Cell Volume (MCV) | 95.4 | fL | OPTIMAL | +4% | Feb 9 |
| RDW MCV Ratio | 0.13 | ratio | OPTIMAL | -- | Feb 9 |
| Mean Cell Hemoglobin (MCH) | 31 | pg | OPTIMAL | -1% | Feb 9 |
| Mean Corpuscular Hemoglobin Concentration (MCHC) | 32.5 | g/dL | NORMAL | -5% | Feb 9 |
| Red Cell Dist Width (RDW) | 12.6 | % | OPTIMAL | -- | Feb 9 |
| Iron | 90 | mcg/dL | OPTIMAL | -11% | Feb 9 |
| Iron Saturation | 23 | % | NORMAL | -21% | Feb 9 |
| Total Iron Binding Capacity (TIBC) | 384 | mcg/dL | NORMAL | +11% | Feb 9 |
| Ferritin | 168 | ng/mL | NORMAL | +5% | Feb 9 |
| Calcium | 9.6 | mg/dL | OPTIMAL | +1% | Feb 9 |
| Marker | Value | Unit | Status | Change | Date |
|---|---|---|---|---|---|
| Insulin-like Growth Factor 1 (IGF-1) | 173 | ng/mL | NORMAL | -- | Nov 21 |
| Z Score | 0.4 | SD | OPTIMAL | -- | Nov 21 |
White Blood Cells
Platelet Count
Lymphocytes
Lymphs (Absolute)
Eosinophils
Eos (Absolute)
Basophils
Baso (Absolute)
Monocytes
Monocytes (Absolute)
Neutrophils
Neutrophils (Absolute)
Mean Platelet Volume
| Marker | Value | Unit | Status | Change | Date |
|---|---|---|---|---|---|
| White Blood Cells | 6.4 | x10E3/uL | OPTIMAL | -12% | Feb 9 |
| Platelet Count | 302 | x10E3/uL | NORMAL | +16% | Feb 9 |
| Lymphocytes | 31.5 | % | OPTIMAL | -11% | Feb 9 |
| Lymphs (Absolute) | 2016 | cells/uL | OPTIMAL | -22% | Feb 9 |
| Eosinophils | 6.1 | % | HIGH | +205% | Feb 9 |
| Eos (Absolute) | 390 | cells/uL | NORMAL | +167% | Feb 9 |
| Basophils | 0.6 | % | OPTIMAL | +20% | Feb 9 |
| Baso (Absolute) | 38 | cells/uL | OPTIMAL | +3% | Feb 9 |
| Monocytes | 7.6 | % | OPTIMAL | +6% | Feb 9 |
| Monocytes (Absolute) | 486 | cells/uL | OPTIMAL | -8% | Feb 9 |
| Neutrophils | 54.2 | % | OPTIMAL | -1% | Feb 9 |
| Neutrophils (Absolute) | 3469 | cells/uL | OPTIMAL | -13% | Feb 9 |
| Mean Platelet Volume | 11.2 | fL | NORMAL | -3% | Feb 9 |
| Marker | Value | Unit | Status | Change | Date |
|---|---|---|---|---|---|
| Homocysteine | 10.8 | umol/L | NORMAL | -- | Nov 21 |
| Vitamin B12 | 442 | pg/mL | NORMAL | -- | Nov 21 |
| Folate (Folic Acid) | 9.3 | ng/mL | OPTIMAL | -- | Nov 21 |
Cortisol
| Marker | Value | Unit | Status | Change | Date |
|---|---|---|---|---|---|
| Cortisol | 6.4 | mcg/dL | NORMAL | -9% | Feb 9 |
Protein, Total
Albumin
Globulin, Total
Bilirubin-to-Albumin Ratio
Albumin/Globulin Ratio
| Marker | Value | Unit | Status | Change | Date |
|---|---|---|---|---|---|
| Protein, Total | 7.1 | g/dL | OPTIMAL | -7% | Feb 9 |
| Albumin | 4.6 | g/dL | OPTIMAL | -4% | Feb 9 |
| Globulin, Total | 2.4 | g/dL | OPTIMAL | -14% | Feb 9 |
| Bilirubin-to-Albumin Ratio | 0.1 | ratio | NORMAL | -- | Feb 9 |
| Albumin/Globulin Ratio | 2 | NORMAL | +18% | Feb 9 |
Castelli Risk Index II
| Marker | Value | Unit | Status | Change | Date |
|---|---|---|---|---|---|
| Castelli Risk Index II | 1.73 | ratio | OPTIMAL | +24% | Feb 9 |